Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer
Starting soon · Not applicable
Conditions studied: Cancer Pediatric
In brief
This is a category 2 human research study (RIPH), interventional, single-center, prospective, open-label. The primary objective of this study is to qualitatively assess the effects of equicoaching on social reintegration in young adults who have been treated for cancer. The secondary objectives are to evaluate the contribution of equicoaching to: 1. Self-confidence; 2. Well-being 3. Quality of life Satisfaction with equicoaching will also be evaluated.
Key facts
- Study ID
- NCT07515274
- Run by
- Centre Leon Berard
- People needed
- 10
- Starts
- 2026-04-05
- Expected to finish
- 2027-01-31
- Last updated by the study team
- 2026-04-13
Who can join
Age: 15 and older, up to 25. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have been treated for a malignant oncological or hematological condition.
- Be between 15 and 25 years of age at the time of cancer diagnosis. This age range corresponds to that chosen by the Leon Berard Cancer Center (CLB) and the Institute of Pediatric Hematology and Oncology (IHOPe) for the Adolescents and Young Adults with Cancer (DAJAC) program
- Have been treated at IHOPe/CLB as part of the DAJAC program
- Have completed intensive treatment within the last twelve months.
- Be able to understand, read, and write French
- Be affiliated with a health insurance plan
- Have been informed about the study and have given consent
- For minors:
- All of the above criteria
- Parent/legal guardian informed about the study and having given consent
You may not qualify if…
- Patient deprived of liberty by judicial or administrative decision
- Pregnant or breastfeeding women
Where it is running
- CLB — Lyon, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.